BioLineRx (NASDAQ:BLRX) Given New $9.00 Price Target at HC Wainwright

BioLineRx (NASDAQ:BLRX) had its price target reduced by HC Wainwright from $21.00 to $9.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of BioLineRx in a research note on Sunday. They set a “hold” rating on the stock.

BioLineRx Price Performance

BioLineRx stock opened at $0.27 on Monday. The stock’s fifty day moving average price is $0.48 and its two-hundred day moving average price is $0.61. The firm has a market cap of $21.72 million, a PE ratio of -0.60 and a beta of 1.48. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. BioLineRx has a one year low of $0.25 and a one year high of $1.89.

Hedge Funds Weigh In On BioLineRx

Several hedge funds and other institutional investors have recently modified their holdings of BLRX. PVG Asset Management Corp acquired a new stake in BioLineRx in the second quarter valued at about $70,000. Atria Investments Inc lifted its holdings in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC acquired a new stake in shares of BioLineRx in the 2nd quarter valued at approximately $462,000. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.